癌症研究
癌基因
蛋白激酶B
淋巴瘤
生物
激活剂(遗传学)
PI3K/AKT/mTOR通路
生殖细胞
白血病
细胞
癌症
细胞生物学
细胞周期
免疫学
信号转导
基因
遗传学
标识
DOI:10.1016/s1357-2725(03)00146-8
摘要
The protein product of the T-cell leukemia/lymphoma 1 (TCL1) oncogene was recently identified as a novel Akt kinase activator. Its crystal structure predicts regions most likely involved in protein-protein interactions, and complex formation is required for TCL1 to activate Akt. TCL1 is expressed in a broad range of normal and malignant lymphoid cell types and in a high proportion of testicular seminomas of germ cell origin, indicating its potential to serve as a novel anti-cancer drug target. This review is focused on the current state of knowledge of TCL1 and the medical implications of its discovery.
科研通智能强力驱动
Strongly Powered by AbleSci AI